Skip to main content

Summary

for people ages 18–99 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.

Official Title

Uptravi® (SelexiPag): tHe usErs dRug rEgistry

Keywords

Pulmonary Arterial Hypertension Hypertension Familial Primary Pulmonary Hypertension Selexipag

Eligibility

You can join if…

Open to people ages 18–99

  • Signed patient informed consent form (ICF).
  • Patients with PAH who either initiate Uptravi at the time of enrollment or have been receiving treatment with Uptravi and have a documented titration regimen (defined as all documented dose changes including, but not limited to: starting dose and highest tolerated dose).
  • Patients ≥ 18 years of age at time of Uptravi initiation.

You CAN'T join if...

  • Patients previously exposed to Uptravi treatment during a clinical trial.
  • Patients that previously discontinued Uptravi for any reason, prior to study enrollment (discontinuation defined as an interruption of therapy greater than or equal to 30 days).
  • Patients enrolled in a blinded clinical trial or in a clinical trial involving an unapproved drug.

Locations

  • UCSF Medical Center accepting new patients
    San Francisco, California, 94143, United States
  • Santa Barbara Cottage Hospital accepting new patients
    Santa Barbara, California, 93105, United States
  • VA Greater Los Angeles Healthcare Center accepting new patients
    Los Angeles, California, 90073, United States
  • University of Southern California accepting new patients
    Los Angeles, California, 90033, United States
  • LA Biomed Research Inst at Harbor UCLA Medical Center accepting new patients
    Torrance, California, 90502, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Actelion
ID
NCT03278002
Study Type
Observational [Patient Registry]
Last Updated
April 17, 2018
I’m interested in this study!